Anika Therapeutics (ANIK) Total Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Total Liabilities data on file, last reported at $179.4 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 5.89% year-over-year to $179.4 million in Q1 2026; TTM through Mar 2026 was $179.4 million, a 5.89% decrease from a year earlier, with the FY2025 full-year figure at $190.3 million, down 6.15% from the prior year.
• Total Liabilities for Q1 2026 stood at $179.4 million, down from $190.3 million in the prior quarter.
• Over the last five years, Total Liabilities for ANIK reached as high as $354.1 million in Q2 2022 and fell as low as $179.4 million in Q1 2026.
• Historically, Total Liabilities has averaged $268.1 million across 5 years, with a median of $263.7 million in 2024.
• Across the five-year window, Total Liabilities increased 0.46% in 2022 and declined 29.48% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $349.1 million in 2022, then declined by 22.48% to $270.6 million in 2023, then dropped by 25.09% to $202.7 million in 2024, then declined by 6.15% to $190.3 million in 2025, then declined by 5.72% to $179.4 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $179.4 million in Q1 2026, $190.3 million in Q4 2025, and $189.4 million in Q3 2025.